businessbriefs
11:35in productionCh. 1 · What Biogen Is/ 11:35 · ceiling 15 min
Companies · Product

Biogen

Cesar Milstein · 1978

Biogen didn’t emerge from Milstein’s lab — it emerged from strategic acquisitions, regulatory gambles, and the hard economics of neurological disease markets.

Biogen is a neurology-focused biotech that built scale via acquisition, not foundational science — and César Milstein, whose hybridoma work underpins modern antibody therapeutics, has no documented relationship to the company.

CompaniesProductMedicinePatentsDiseaseMedicine across the network →
Chapters & takeaways6
  1. 0:57
    What Biogen Is

    Biogen is a U.S.-based biotech firm founded in 1978, focused exclusively on neurological diseases.

  2. 2:20
    Where the Money Comes From

    Over two-thirds of Biogen’s 2024 revenue came from six neurological drugs — none derived from monoclonal antibodies.

  3. 4:01
    How It Grew

    Biogen grew through targeted acquisitions — not internal discovery — buying Fumapharm, Conforma, and Syntonix in rapid succession.

  4. 5:26
    What Went Wrong

    Tysabri’s association with PML in 2008 exposed the clinical and reputational cost of fast-tracking high-efficacy neurotherapies.

  5. 6:53
    Milstein Had Nothing to Do With Biogen

    Milstein co-developed the hybridoma technique in 1975 and patented monoclonal antibody production — but had no connection to Biogen.

  6. 8:01
    The Field vs. The Firm

    Milstein’s work enabled the broader biotech industry — but Biogen’s own pipeline bypassed monoclonal antibodies entirely.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • clinical asset acquisition
  • neurology market concentration
  • post-approval risk management
What does not
  • César Milstein founded Biogen
  • Biogen developed monoclonal antibodies
  • Biogen’s pipeline stems from hybridoma technology
Study it if
  • biotech strategists
  • regulatory analysts
  • pharma historians
Skip it if
  • antibody researchers
  • Milstein biographers
  • startup founders seeking origin myths
The written brief1 min read

What the company or idea is

Biogen is a U.S.-based multinational biotechnology company founded in 1978 and headquartered in Cambridge, Massachusetts, specialising in neurological disease treatment.

How it actually makes money

Biogen makes money by commercialising neurological disease treatments — primarily MS drugs like Tecfidera and AVONEX, SMA drug Spinraza, and newer therapies like Qalsody and Skyclarys — with these products accounting for over two-thirds of 2024 revenues.

What works

Acquisitions like Fumapharm AG and Syntonix Pharmaceuticals delivered pipeline assets (Fumaderm, BG-12, hemophilia B drug) and platform tech (inhalable delivery); licensing and spin-offs (Bioverativ) extracted value from non-core assets.

What does not

Biogen does not own or operate the hybridoma technique. César Milstein developed it in 1975; he did not found Biogen, nor is there any link between him and the company in the source material.

What to take from it

The gap between Biogen’s origin story and its actual scientific lineage matters: it built its business on fumarates and interferons, not monoclonal antibodies — despite the field Milstein helped create enabling much of modern biotech.

Is it worth your time

Yes — but only if you are studying how biotech firms pivot from antibody science to neurology, manage clinical risk (e.g., PML), and monetise legacy assets while navigating regulatory reversals like Aducanumab’s abandonment.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Blackstone Inc.

Stephen Schwarzman · 1985 · 10:42

Blackstone didn’t build a firm — it built a permission structure for capital.

Play nextBack to Companies
10:42